CPSA Europe 2018

Presentation Abstract

Remote Sampling – Impact for Innovative Clinical Trials

John Farrell
GlaxoSmithKline

Symposium Session 1
Wednesday, February 7
9:45 am - 11:15 am

In recent years there have been rapid developments in respect to innovative digital approaches in clinical trials. This includes; wearable sensors, patient engagement solutions and patient connectivity. Pharma has sought to leverage such advances to enable “direct to patient” or “virtual” clinical trials, where the patient participates in clinical trials from their home.

The benefits include greater inclusion, especially for patients who are unable to attend clinic visits or reside in remote communities, as well as the collection of clinical data more representative of the patients real world situation.

As blood assessment remains a standard component for most clinical trials, patients still have to attend clinic phlebotomy draws, so limiting the premise technology offers. We hope that by developing effective home-based remote/micro-sampling we can create a paradigm shift, to realise the value technology offers in this space with a significant benefit to patients.

About John Farrell
John leads the Digital Delivery and Imaging team at GlaxoSmithKline which works closely with clinical study teams in bringing innovation into the clinical setting. Ensuring robust evaluation of key risk areas such as regulatory, privacy, GCP and safety. Prior to this, John was head of the late-phase clinical imaging team at GSK and before this managed a study management team in Oncology. John has been with GSK for 14 years and worked previously in Japanese Pharma and contract research organisations. John as a degree in Biomedical Sciences and an MBA.